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Abstract: Endometrial cancer (EC) is the most frequent gynecological cancer. In patients with
relapsed and advanced disease, prognosis is still dismal and development of resistance is common.
In this context, endometrial Cancer Stem Cells (eCSC), stem-like cells capable to self-renewal and
differentiation in mature cancer cells, represent a potential field of expansion for drug development.
The aim of this review is to characterize the role of eCSC in EC, their features and how they could
be targeted. CSC are involved in progression, invasiveness and metastasis (though epithelial to
mesenchimal transition, EMT), as well as chemoresistance in EC. Nevertheless, isolation of eCSC
is still controversial. Indeed, CD133, Aldheyde dehydrogenase (ALDH), CD117, CD55 and CD44
are enriched in CSCs but there is no universal marker nowadays. The most frequently activated
pathways in eCSC are Wingless-INT (Wnt)/β-catenin, Notch1, and Hedghog, with a high expression
of self-renewal transcription factors like Octamer binding transcription factor 4 (OCT), B Lymphoma
Mo-MLV Insertion Region 1 Homolog (BMI1), North American Network Operations Group Homebox
protein (NANOG), and SRY-Box 2 (SOX2). These pathways have been targeted with selective drugs
alone or in combination with chemotherapy and immunotherapy. Unfortunately, although preclinical
results are encouraging, few clinical data are available.
Keywords: cancer stem cell; endometrial cancer; target therapy
1. Introduction
Endometrial cancer (EC) is the most common gynecological tumor in developed countries. Rates
for new diagnosis have been rising on average by 1% for each year over the last 10 years, with an
incidence of 79 cases per 100,000 women in Europe and a median age at diagnosis of 62 years [1,2].
Known risk factors are early menarche, late menopause, polycystic ovary syndrome (PCOS),
infertility, obesity and diabetes although genetic predisposition with presence of Lynch Syndrome is
fundamental in patients with diagnosis before the age of 50 [3–5].
Historically, sporadic EC has been divided in two pathogenetic types, according to the so-called
Bokhman’s dualistic model: estrogen-dependent endometrioid (Type 1) and estrogen-independent
non-endometrioid carcinomas (Type 2) [6]. Almost 80% of EC type I patients had lower grade (G1
or G2) tumors, while 20% had high grade (G3) tumors [6]. They usually have low potential for
lymphovascular invasion, high estrogen (ER) and progesterone receptors (PgR) expression, and a
favorable prognosis [6]. Type II EC is characterized by prevalence of high grade (G3) (66% versus 34%
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low grade), high potential for lymphovascular invasion, low progesterone sensitivity, and a dismal
prognosis [6].
Although Bokhman’s dualistic model is still relevant in clinical practice, more recently, the Cancer
Genome Atlas (TCGA) has proposed a molecular classification defining four EC types with different
clinical outcomes, on the basis of their overall mutational burden, specifically p53, polymerase episilone
(POLE), and phosphatase and TENsin homolog (PTEN) mutations, microsatellite instability (MSI),
and histology [7].
About one third of patients have localized cancer at diagnosis [1]. The prognosis for EC patients
with early-stage or localized disease (stage I and II) is generally favorable. The majority of them can
be successfully cured with surgery alone or followed by brachytherapy (BT) and/or external beam
radiation therapy (EBRT) [8–11], with the addition of platinum-based chemotherapy in stage I high
risk and in stage II patients [12]. The 5-year overall survival (OS) is 95% for stage I and 69% for
stage II [1]. Nevertheless, about 13% of high-risk patients and 3% of low risk patients recur [13,14].
Prognosis for recurrent and advanced disease (stage III or IV) is poor, with 5-year OS in patients with
metastatic disease rates ranging from 15 to 17% [1]. Standard first line treatments are a combination of
carboplatin and paclitaxel and therapeutic options beyond first-line are limited, with low response
rates to either single agent chemotherapy or endocrine therapy with medrossiprogesterone acetate
(MPA) [12], due to the rapid onset of resistances. New drugs have been developed among which the
checkpoint inhibitors showed interesting activity, leading to FDA approval of Pembrolizumab alone in
MSI high tumors but also in combination with an angiogenesis inhibitor (Lenvatinib) in EC without
MSI [15–18]. Nevertheless, new therapeutic approaches are still needed to significantly improve the
prognosis of women with recurrent or advanced EC.
The basis of cancer stem cells (CSCs) theory is one of the most intriguing strategies to overcome
drug resistance exploits stemness related pathways.
Historically, cancer research and therapies were based on the theory of clonal evolution, which
stated that neoplasms derive from the sequential expansion of preexisting somatic mutations [19].
This theory leaves some open questions including the evidence of clonal heterogeneity of tumors [20],
allowing the development of drug resistance [21]. More recently increasing evidence has led to the
formulation of the so-called CSCs theory, which assumes that tumors, similarly to normal tissue, are
composed by cells at different maturation stages including also CSCs. A CSC is a cell with stem-like
properties, which has originally acquired the oncogenic mutation and gains the possibility to self-renew
and to differentiate, being responsible for the generation of the entire neoplastic cell population and of
their heterogeneity, drug resistance and invasiveness [22].
The first evidence supporting the CSC theory was derived from Virchow and Cohnheim studies [23].
These data were confirmed from a preclinical study published by Bonnet et al in 1997 demonstrating
that cells capable to generate human AML (Acute Myeloid Leukemia) in xenograft models had
proliferative capacities and the ability to differentiate and self-renew indicating that normal stem
cells, rather than committed progenitor cells, were the target for the neoplastic transformation [24].
Since then, the presence of CSC has been reported in several different type of tumors including
breast [25], colorectal [26–28], prostatic [29], central nervous system cancers [30], melanomas [31] and
sarcomas [32].
Nevertheless, new data from high throughput sequencing, described new cancer models, among
which the so-called big bang model. In this model, initiating cells grow producing several subclones with
clonal alterations that are pervasive but not submitted to clonal selection while new subclonal mutations
will be generated thanks to replication errors in smaller and smaller populations, conferring survival
advantage and causing intratumor heterogeneity [33]. All these theories, far from being opposite,
integrate and complete each other, describing and justifying presence of pervasive mutations but also
tumor heterogeneity, drug resistance and above all plasticity. Indeed both CSC and differentiated
cancer cells show plasticity, that is the capability of a phenotypic transition if stimulated [34]. Plasticity
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connects both CSCs and differentiated cells to microenvironment, with cells that move “up and down
the hierarchy of differentiation” thanks to genomic instability and justifies once more heterogeneity [34].
During the last decades, several therapeutic strategies against CSCs have been attempted;
some successful examples are represented by differentiation therapies for the treatment of acute
leukemia [35–37], imatinib for gastrointestinal stroma tumors (GIST) [38] and sonidegib in basal cell
carcinomas (BCC) [39]. Following these proofs of principle results, several inhibitors of signaling
pathways [40,41], modulators of epigenetic mechanisms that regulate CSCs functions [42], or adoptive
cell therapy targeting specific CSC antigens [43–48] are under clinical investigation.
The aim of this review is to describe the role of CSC in EC, their features, the most frequently
involved pathways and how they could be targeted on the basis of preclinical evidence and
clinical studies.
To do this, we performed a research on Pubmed and clinical trial.gov using the keywords “Cancer
Stem Cells” and “Endometrial Cancer”.
2. CSCs in Endometrial Cancer: Role and Biomarkers
Hubbard et al. provided the first evidence of CSCs in ECs: small populations of cells obtained
from EC samples generated tumors in immunocompromized mice. The morphology of daughter cells
was similar to parental tumor, indeed they expressed cytokeratin, vimentin, estrogen receptor-α (ERα),
and PgR [49] suggesting that a small population of cells is able to maintain features of parental tumor
and to differentiate in vivo.
Self-renewal capacity, de-differentiation and ability to migrate from primary mass to blood vessels
and other organs are the distinctive features of CSCs [50]. The self-renewal capacity is the property
of CSCs to regenerate, leading to a subset of cells that aberrantly differentiates and survives despite
the negative feedback signals of apoptosis [50]; this phenomenon seems to be at the basis of the
tumor development and maintenance [51]. On the other hand ability to migrate but also to induce
angiogenesis and to produce extracellular matrix plays a key role in EC metastasis [50]. Lastly CSCs
are intrinsically chemoresistant, on the basis of their plasticity, playing a role in low response rate to
chemotherapy in this disease [52].
To date, three theories have been postulated on the “origins” of endometrial CSCs.
The first hypothesis assumes that CSCs arise from normal/adult stem cell (SSC). The progressive
acquisition of genetic mutations and epigenetic alterations may lead to CSCs transformation [53].
Current evidence suggests that CSCs could originate from differentiated tumor cells: the expression
and release of “steamness” molecules seems to induce a de-differentiation program [54].
Finally, the somatic and differentiated cells of endometrium could represent the CSCs progenitor
with acquisition of self-renewal and plasticity properties [52].
Regardless “origins”, an important issue is definition of biomarkers that can identify CSCs.
Different molecules were studied as markers of stemness in ECs [55]. To describe the main
biomarkers, we performed research on Pubmed using the keywords “Cancer Stem Cells” and
“Endometrial Cancer”, manually selecting papers on this topic. We excluded articles before 2010 and
those not in English language.
CD117 (c-kit) is a cell-surface receptor tyrosine kinase type III that, if stimulated by Stem Cell Factor
(SCF), induces cell replication, survival and differentiation and has been assumed to be a CSC marker
for several tumors [56–58]. It has been shown that CD117+ EC cells showed a greater proliferative
and colony forming capacity in a SCF-dependent manner. Indeed, using an anti-SCF antibody,
the colony-forming activity decreased in vitro [59]. High CD117 expression was also recognized as an
independent prognostic factor for OS [59]. CD44 and CD55 are others transmembrane proteins related
to EC stemness. CD44 is an adhesion molecule implicated in process of invasion and metastasis and
has been studies as marker of CSCs in ECs [60–62]. Indeed the spheres generated from EC cell lines
showed CD44 expression [60] with evidence also of co-expression of CD44 and CD133 in endometrial
CSCs [63].
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Saygin et al. reported CD55, an intrinsic cell surface complement inhibitor, as highly expressed in
endometrioid ovarian and endometrial CSCs and recognized that CD55+ cells were able to regulated
self-renewal and cisplatin-resistance more than CD55− ones [64].
All markers previously described are highly expressed in cells with in vitro stem cell properties
while a “side-population” (SP) and CD133, listed below, are not only expressed in CSC in vitro, but
also in cells transplanted in vivo.
Cluster of Differentiation (CD) 133, also known as prominin-1, is a member of pentaspan
transmembrane glycoproteins, which specifically localize to cellular protrusions. Although the function
of CD133 is not yet clear, a role in the organization of the cell membrane has been hypothesized [65].
Several authors have identified CD133 as a potential marker of CSCs in different solid tumors including
brain [30], prostate [66], colon [27] and ovarian cancers [67,68]. Rutella et al. analyzed 113 tumor
samples of EC and demonstrated that isolated CD133+ cells showed a more aggressive proliferation
in vitro, a greater colony-forming ability and an higher resistance to cisplatin and paclitaxel compared
with CD133− cells [63]. Moreover, when serially transplanted into immunocompromized mice, CD133+
cells were capable of generating tumors characterized by a phenotype comparable with the one of the
original tumor [63]. The role of CD133 as marker of tumorigenic potential in EC cells was confirmed
by various works [61,62,69–71].
Several preclinical studies identified SP in cancer cell lines, defining a cellular phenotype capable of
active draining fluorescent dye Hoechst 33342 outside cytoplasm [72]. SP cells are, indeed, characterized
by a high expression of ABCG2 proteins, a super-family of ATP-binding cassette (ABC) transporters.
These proteins facilitate efflux of proteins, lipids, ions, and above all, an anti-cancer drug, inducing
chemoresistance [73,74].
Kato et al. [75] proved that a SP subpopulation is represented in human EC cells and rat
endometrial cells with activated KRAS gene. These cells showed proliferative and self-renewal capacity,
enhancement of migration, tumor formation and chemoresistance [75–78]. Nakamura et al. identified
an SP fraction from EC cell lines with CSC features that co-expresses CD133. SP cells phenotype and
CD133 expression seem to be independent markers of stemness and their co-expression is correlated to
higher proliferation rate and tumor formation [77].
When transplanted in nude mice, SP cells generate large and invasive tumors composed by both
tumor cells and stromal-like cells producing extracellular matrix. SP derived tumors express higher
levels of vimentin, α-smooth muscle actin, collagen III and fibronectin than non-SP derived tumors, all
markers of mesenchymal differentiation [75,76].
Indeed, Epithelial-to-mesenchymal transition (EMT) is an essential process during early embryonic
development as well as a mechanism involved in cancer progression [79]. The EMT pathway allows
malignant cells to metastasize from a primary tumor by losing epithelial features and obtaining
mesenchymal phenotype [79]. These evidences suggest that endometrial cancer SP cells are also
capable of undergoing EMT.
Lastly Aldehyde dehydrogenase 1 (ALDH1) is one of the 19 different enzymes involved in
oxidation of Aldeide [80]. It shows high activity in early stages of stem cell differentiation [81,82].
EC cells that express high ALDH1 are more tumorigenic, invasive and resistant to cisplatin than low
expressing ALDH1 cells. High expression of ALDH1 correlates with a worse prognosis in EC patients
(p = 0.01 for Overall Survival (OS)) [83]. Kitson et al. compared CD133+ cells to high ALDH1 cells,
showing that the latter had greater CSCs activity and higher expression of genes involved in EMT than
CD133+ cells [84].
A recent work conducted by Tabuchi and colleagues demonstrated heterogenic CSCs populations
in EC [85]. They isolated two distinct types of clones from one patient tumor sample, according to their
growth pattern: the sphere clones (S clones), that grow forming spheres, resistant to chemotherapeutic
agents but less tumorigenic and leukemia-like clones (LL clones), that grow separately, like leukemia
cells, sensitive to chemotherapy but highly tumorigenic [85]. These results reveal that in the same
sample there are different CSCs, suggesting that probably there is not a unique biomarker that can
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identify CSCs in EC and that different biomarkers could be expressed by different colonies in the
same tumor.
This leads also to absence of consensus on the optimal technique to separate CSC from differentiated
cells. Indeed, different approaches have been developed, among which fluorescence activated cell
sorting, individuation of SP, with and without the use of Hoechst 33342, and use of a serum free
suspension cultivation with the addition of growth factors. Specifically, this medium drives to formation
of microsphere, proliferation of CSCs and elimination of differentiated cells [86].
3. Activated Pathways in Endometrial CSCs
Stemness in EC is regulated by different pathways among which Notch, Wnt, and Hedgehog
pathways seem to have the most relevant roles.
Notch signaling pathway regulates cell development and differentiation. It is highly conserved in
most mammals and implicated in many mechanisms that control multiple cell differentiation processes
during embryonic and adult life [87].
Notch signaling cascade keeps the undifferentiated state of cells but can also induce cell
differentiation under appropriate stimulation. Several evidences showed that dysregulated Notch
signaling is involved in tumorigenesis and cancer development being overexpressed in breast cancer,
gastric cancer, colon cancer and pancreatic cancer [88].
Musashi-1 is an RNA binding protein involved in Notch-1 signaling pathway: Götte et al.
showed an increased expression of Musashi-1 protein in endometriosis and endometrial carcinoma
and expression of Small interfering-RNA (siRNA), able to inhibit Musashi- 1, in EC cells, reduces cell
proliferation inducing also apoptosis [89].
Nanog is a key multidomain homeobox transcription factor, placed on the chromosome 12,
which contributes to the maintenance of the undifferentiated state of pluripotent stem cells. Nanog
downregulation induces cell differentiation. Several studies link Nanog overexpression to EC
cells [49,90]. Transcription factors octamer-binding transcription factor 4 (Oct4), SRY-Box 2 (SOX2),
Transcription Factor 3 (Tcf3) and Forkhead Box D3 (FoxD3) contribute to the regulation of Nanog
expression. OCT-4 and SOX-2 were found in endometrial CSCs and linked to the potential of
self-renewal capacity [49,90].
The Wnt pathway (or Wnt/β-catenin pathway), known as the canonical pathway, is involved in
several processes that are essential for embryonic development and normal adult homeostasis [91].
The canonical pathway requires Wnt ligand binding to Frizzled receptors to initiate the intracellular
signaling via β-catenin nuclear translocation. The phosphorylation of a negative regulator of the
destruction complex, Dishevelled (Dvl), causes the recruitment of Axin, inhibiting its interaction with
other components of the destruction complex. Thus, ß-catenin accumulates in the cytoplasm and
translocates to the nucleus, where it activates the transcription of Wnt related genes as cyclin-D1 and
MYC (MYC Proto-Oncogene, Basic Helix Loop Helix (BHLH)Transcription Factor) [91].
Alterations in Wnt signaling have been related to the development of many different malignancies,
including acute myeloid leukemia (AML), breast and gastrointestinal cancers [92]. Kusanoki and
collegues have shown that in endometrial cancer downregulation of Wnt signals leads to inhibition of
proliferation and migration of endometrial CSC [76].
As described above, EMT is a process related to stemness in ECs. In the work of Yusuf et al. Secreted
Protein Acidic and Rich in Cysteine (SPARC) a protein involved in extracellular matrix synthesis is
expressed in poorly differentiated endometrioid adenocarcinoma with enhanced fibronectin expression
and promotes migration and formation of tumor stroma [78].
In a recent work by Lu and colleagues the expression of SPARC-related modular calcium-binding
2 (SMOC–2), a member of SPARC family, was found to be higher in endometrial CSCs [93]. High Levels
of SMOC-2 positively correlate with the expression of CD44 and CD133. Moreover, they demonstrated
that SMOC-2 is involved in activation of Wnt/ β-catenin pathway and is related to cisplatin and
paclitaxel resistance [93].
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Also, (PTEN-Phosphoinositide 3 kinases (PI3K)-Protein kinase B (AKT)-Mammalian target of
rapamycin (mTOR) pathway plays a role in maintaining stemness through the upregulation of EMT
inducers such as B Lymphoma Mo-MLV Insertion Region 1 Homolog (BMI-1) , that downregulates
PTEN expression, Enhancer of zeste homolog 2 (EZH2) that participate to histone methylation, Slug
and Snail, that downregulate E-caderin expression [94].
Hedgehog signaling pathway acts on embryonic cells growth and differentiation. Its downstream
effector is a transmembrane protein, Smoothened (SMO) that activates Glioma (Gli) transcriptional
factor 1 and expression of target genes at the end. Their activity is regulated by the membrane receptor
patched (Ptch1) [95]. Feng and colleagues showed that expression of Sonic Hedgehog and SMO
is significantly higher in ECs if compared with normal Endometrial epithelium and endometrial
hyperplasia [96].
Lastly, not only genetic pathways but also epigenetic modulators and metabolic preferential
pathways are important in maintaining cancer stemness. For example the expression of high levels
of micro-RNA 21 in ECs have been shown to downregulate PTEN expression, leading to EC cells
proliferation [97]. A preferential oxidative pathway with a higher glucose uptake and a lower lactate
production could differentiate CSC from differentiated tumor cells [98].
In conclusion, several pathways are involved in EMT and self-renewal properties of endometrial
CSCs: these pathways are strictly interconnected and some of them are under investigation as possible
targets of therapy.
For the most important CSC pathways and how we could target them, see Figure 1.
The most frequently activated pathway in CSCs are:
Hedgehog signaling pathway, with its downstream effectors SMO and Gli1; its inhibitors are sonidegib
and cyclopamine.
PI3K/AKT/mTOR Complex (mTORC)pathway, inhibited by everolimus and metformin.
Wnt/β-catenin pathway, inhibited by salinomycin and ETC-159.
NOTCH pathway whose inhibitors are DAPT ((N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine
t-butyl ester))), Enoticumab and NOV1501 (also ALB001).
Other agents target transmembrane proteins like CD55 (saracatinib) or transcription factors
involved in maintening stemness like upstream and downsteam inhibitors of Signal transducer and
activator of transcription 3 (STAT3)(ruxolitinib, nifuraxozide and itacitinib), inhibitors of B Lymphoma
Mo-MLV Insertion Region 1 Homolog BMI-1 (like PTC-028) or modulators of p53 (like CP-31398 and
PRIMA-1).
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Figure 1. Activated pathways in Endometrial Cancer Stem Cells (CSCs) and their inhibitors.
4. Agents Targeting CSCs in EC: Preclinical Development
As described before, CSCs play a main role in tumor progression and chemoresistance. Following
those evidences many new molecules have been developed, in order to target distinctive pathways
of stemness.
Interesting targets are membrane proteins, for example CD55 or CD117, that also regulate SOX2,
NANOG and OCT4 expression, maintaining self-renewal and induce drug resistance. Saygin and
colleagues demonstrated that inhibition of CD55 with saracatinib produces cisplatin resensitization
of both ovarian and endometrial endometrioid cell lines while Zhang and colleague demonstrated
that cisplatin resistant CSCs are sensitive to imatinib [59,64]. Another target evaluated in preclinical
setting was ALDH1. Inhibition of ALDH activity with disulfiram and N, N Diethylaminobenzaldehyde
(DEAB) reduces proliferation of spheroids composed by CSCs [99]. On the other hand, an antibody
directed against Epithelial membrane protein-2 (EMP2) (a protein involved in tumor migration and
neoangiogenesis) reduces tumor formation and growth in ALDH1+ cells and indirectly downregulates
ALDH1 expression although the precise mechanism of action is not clear [100]. Another mechanism
that induces chemoresistance and CSC survival is autophagy which is probably related to ALDH
expression. Xiaomin Ran and colleagues demonstrated that with the addition of an autophagy inhibitor
[3-methyladenine (3-MA) or Cloroquine (CQ)] to EC cultured spheroids, there is a reduction in cell
growth and self-renewal capability [101].
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As described above NOTCH signaling is responsible of CSC viability and proliferation.
Preclinical works demonstrated that selected miRNAs inhibit this pathway. For example
miRNA134 inhibits proliferation in vitro and in vivo of CD44+/CD133+ subpopulation in type II
EC, suppressing Protein O-glucosyltransferase 1 (POGLUT1) expression, that is a regulator of
NOTCH signaling [102]. MiRNA-34a acts directly against NOTCH1 reducing tumor formation
in Patients derived Xenografts (PDXs). It also reduces expression of vimentin, EMT and invasiveness of
HEC-1-B cells [103]. This paved the way for development of NOTCH inhibitors, among which DAPT
(N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester)) showed to synergize with an
Epithelial growth factor receptor (EGFR) inhibitor (AG1478) in HEC-1A and IK cell lines reducing cell
viability [104].
Most preclinical studies focused on Wnt/β-catenin pathway inhibition. Liu and colleagues
demonstrated that Membrane Associated Ring-CH-Type Finger 7 (MARCH7) is a key protein in EMT
and cancer stemness. It indeed increases Vimentin and Snail levels in EC cells. Its inhibitor miR-27b-3p
reduces the migration and invasion of Ishikawa cells and downregulates EMT related proteins [105].
A molecule that targets this pathway is Salinomycin, a monocarboxylic polyether antibiotic.
It inhibits proliferation of eCSC from human and rat lines and reduces levels of fibronectin, BCL2
and cyclin-D that are downstream Wnt pathway [76]. Salynomicin acts also inhibiting ABC proteins,
overcoming thus drug resistance mediated by these efflux pumps in CSCs [106]. These pumps have been
exploited also by Yaguchi and colleagues. They indeed demonstrated that ABC proteins are induced by
estrogens and controlled via Sirtuin 1/cAMP response element binding protein (SIRT1/CREB) signaling
pathway. Its inhibitor reserpine reduced E2-induced cell proliferation and viability [107].
Also, inhibition of Hedghehog pathway could be an interesting strategy. Targeting Hedgehog
with cyclopamine reduces EC cells viability between 56% and 67% in two different ER+ cell lines at
72 h, with a downregulation of cyclin D1 and N-myc in HHUA cells [96].
Among transcription factor, BMI-1 play a key role in EMT and PI3K/AKT but also in Notch and
Hedgehog downstream pathways. Indeed inhibition of BMI-1 with a si-RNA, induces a reduction of
number of CSCs (with a lower expression of SOX2 and Oct4) and of cancer invasiveness [108]. PTC-028,
a second-generation inhibitor of BMI-1, decreases invasion of ECs and activates caspase-dependent
apoptosis [109].
Targeting Signal transducer and activator of transcription 3 (STAT3) demonstrated to be a
resourceful tool. Both inhibiting upstream pathways like Interleukin 6 (IL-6) pathway with an antibody
directed against the CD126 receptor or with a miRNA (mir326 bound to a nanoparticle 326@SPION)
against G Protein-Coupled Receptor 91 (GPR91) pathway both using small molecule directed against
STAT3 (nifuroxazide) and against Janus kinase 1 (JAK1- ruxolitinib) reduces in vitro and in vivo
ALDH+ HEC1A cells proliferation and sensitize CSCs to cisplatin [110,111].
Inhibition of other transcription factors acting on embryonic development was studied in preclinical
setting, among these miRNA194 inhibits SOX3 expression, a high-mobility group box protein that is
involved in EMT and stemness of EC. It directly binds 3-untranslated region (UTR) of SOX3, reducing
growth and metastasis of EC tumorspheres [112].
Other drugs inhibit CSCs growth, although their activity involves also non-CSC specific pathways,
such as drug metabolism, epigenetic or hormone dependency.
Being known that estrogens stimulate growth of ER+ CSC spheroids with upregulation of IL6, IL1B
an IL18 [99], Guy and colleagues showed that MPA decrease CD133+ populations both in ER+/PgR+
but also in ER−/PgR− cell lines. Moreover there was a reduction in CD133+ cells in samples of patients
who responded to MPA treatment although number of samples was small (only 4 patients) and they
all showed ER positivity [113].
Histone deacetylase inhibitors (like Sodium Butyrate) reduce viability of EC cell lines with an
enhanced activity on CSCs through DNA damage and overproduction of Reactive oxygen species
(ROS) [114].
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Inhibition of PI3K pathway both with a si-RNA acting against BMI-1 as described above [108]
or with Metformin reduces CSCs activity. Metformin is active on CSCs at a high dose (0.5–1 mM)
both reducing cell proliferation and CSCs related genes expression but it doesn’t act on self-renewal
capacity [84]. Moreover patients’ derived adipocyte media reduces cell response to metformin
suggesting that microenvironment can influence responsiveness of CSCs to this drug [84].
Modulators of p53, like CP-31398 and PRIMA-1, reduce viability and growth of ALDH-expressing
cells, suggesting an activity of these compounds on stemness related pathways [99].
For the most important drugs acting on CSCs see Figure 1.
5. Agents Targeting CSCs in EC: Clinical Trials and New Perspectives
As for clinical activity, several early phase studies are evaluating drugs targeting CSCs pathways
in EC patients.
Regarding agents directed against PI3K pathway their possible role in the treatment of EC patients
has been widely investigated in clinical studies. They have showed interesting activity in pretreated
ECs patients. Phase II trials evaluated mTOR inhibitors alone and registered a 4% of Response rate
(RR) with temsirolimus ev [115], up to 5% with everolimus [116] and between 8.8 and 11% of RR with
ridaforolimus [117,118]. Most common Adverse events (AEs) included anaemia, mucositis, fatigue,
hypercholesterolemia and hyperglycemia. On the basis of crosstalk with ER pathway, combinations
were studied with the aim of improving activity of these compounds. The first attempt with a
combination of temsirolimus , megaestrol acetate and tamoxifen was unsuccessful with no increase in
RR compared to temsirolimus alone but a higher percentage of venous thromboembolisms [119].
On the other hand, in a phase II trials, patients receiving a combination of letrozole and everolimus
achieved a RR of 32% with a manageable toxicity profile leading to its inclusion as a therapeutic
option for advanced EC in National Comprehensive Cancer Network (NCCN) guidelines [120].
Activity of metformin in EC was also evaluated in clinical trials, retrospective series and a systematic
meta-analysis suggesting that patients using metformin had a higher OS compared to controls
(Hazard Ratio (HR) = 0.82; Confidence Interval (CI): 0.70–0.95; p = 0.09) [121]. On the basis of these
promising results, Soliman et al evaluated a combination of everolimus, letrozole and metformin
achieving a 29% of Partial Response (PR) (14 over 48 patients evaluable) with a safe profile; diarrhea,
anemia, fatigue, nausea, mucositis, hypertriglyceridemia, and high transaminase were the most common
adverse events [122]. Other ongoing studies are evaluating even more powerful combinations that
target not only the PI3K/AKT pathway and Endocrine Receptors but also cell cycle [123] (NCT01797523,
NCT03008408).
Among strategies that directly target CSCs pathway, agents acting on Notch have been studied.
Delta like 4(DDL4) is a Notch ligand specifically expressed in endothelial cells. In a phase I trial
Enoticumab, a DLL4 inhibitor, was evaluated among 54 patients with advanced solid tumors showing
a safe profile with G3 nausea and vomiting as dose limiting toxicities (DLTs) and initial data of activity
with a Response Rate RR of 5% and a stable disease in 16% of patients [124]. Another DLL4 inhibitor
(NOV1501, also ABL001) is under investigation also in EC (NCT03292783).
Signature program is an ongoing platform of basket trials among which solid tumors with
alteration of Hedgehog pathway could receive Sonidegib, an inhibitor of SMO (NCT02465060) [125].
Indeed Sonidegib showed a safe profile in a phase I trial with increased serum creatinine as the most
frequent G3/G4 Adverse events (AE) (17% of patients) [39] and is approved for the treatment of adult
patients with locally advanced BCC [126].
Among strategies developed to target Wnt pathway, inhibitors of Porcupine, an acetyltransferase
involved in secretion of Wnt ligands, have been studied in early phase clinical trials [127]. ETC-159 is a
Porcupine inhibitor. It shows manageable side effects in interim analysis of a phase I trial in which this
agent was evaluated in combination with denosumab in 5 patients. Dysgeusia (62%), fatigue (37%),
weight loss (37%), back pain (37%) and headache (37%) were the most frequent AEs [128]. An ongoing
trial is evaluating ETC-159 in endometrial cancer alone or in combination with pembrolizumab
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(NCT02521844). This trial is one of several attempts to exploit immune microenvironment to target
also CSCs on the basis of immune suppression induced by stem related pathways such as β-catenin in
the Wnt signaling [129].
The few studies available suggest a safe profile of these drugs however data on activity are
still awaited.
For a list of main ongoing trial targeting CSCs in ECs see Table 1.
Table 1. Ongoing clinical trials targeting Cancer Stem Cells (CSCs) in Endometrial Cancer.
Description Condition Line ofTherapy
Primary
Endpoint Phase Status
Trial
Identifier
Targeted Therapy Directed by
Genetic Testing (Pi3k inhibitors,
AKT inhibitors,
Hedgehog Antagonist)
Advanced
solid tumors ≥2 line ORR II Recruiting NCT02465060
DKN-01 +/− Paclitaxel EC, OC orCarcinosarcoma ≥2 line
ORR, toxicity,
pharmacokinetic II Recruiting NCT03395080
ETC-159 +/− Pembrolizumab
EC, OC or
colorectal
cancer
≥2 line % AE I Active notrecruiting NCT02521844
COTI-2 (Against p53) +/−
cisplatin
EC or Other
solid tumors na
DLT, MTD,
RP2D I Recruiting NCT02433626
Everolimus, Letrozole,
and Metformin EC ≤3 line CBR II
Active not
recruiting NCT01797523
Ribociclib+
Everolimus +
Letrozole
EC ≤ 3 line DLT/CBR I/II Recruiting NCT03008408
Gedatolisib + Palbociclib Solid tumors NA MTD, RP2D,%AE I Recruiting NCT03065062
Cyclophosphamide +
Metformin + Olaparib EC ≥2 line RP2D I/II Notyetrecruiting NCT02755844
AZD2014(MTOR inhibitor)
+ anastrozole ER
+ EC ≥2 line % AE,8weeks PFS I/II Recruiting NCT02730923
NOV1501 (anti DLL-4) Solid tumors NA DLT I Recruiting NCT03292783
Itacitinib (anti Jak 3)
(INCB039110) and/or
Pembrolizumab
Solid tumors NA Toxicity I Active notrecruiting NCT02646748
Legend: AEs: Adverse Events, CBR: Clinical Benefit Rate; DLTs: Dose Limiting Toxicities; EC: Endometrial
Cancer; ER+: Estrogen Receptor positive; MTD: Maximum Tolerated Dose; NA: not available; OC: Ovarian Cancer;
ORR: Overall Response Rate; PFS: Progression Free Survival; RP2D: Recommended Phase II Dose.
6. Discussion
CSCs play a main role in cancer progression and drug resistance. Their expression in EC correlates
with tumor aggressiveness and chemoresistance. Different biomarkers have been developed to detect
and isolate CSC, both transmembrane proteins and dynamic tests or enzymes like ALDH1. Among
these, EMT plays a role both as a marker of stemness and an activated pathway. Other pathways
involved in cancer stemness are Hedgehog signaling pathway, PI3K/AKT/mTOR Complex (mTORC)
pathway and NOTCH pathway. These pathways have been exploited therapeutically and early phase
trials suggest that both NOTCH inhibition with Enoticumab and Hedgehog inhibition with Sonidegib
could be active against endometrial CSC. Nevertheless, combination of drugs that exploit PI3K related
pathways seems to be the most promising strategy.
Several questions are still open:
• Which is the best biomarker to detect CSCs?
• Is there a dependency on a specific pathway?
• Which is the most promising strategy to target CSCs?
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• Probably CSCs heterogeneity justifies the presence of multiple biomarkers [85]. Indeed,
CD133 and ALDH1 are the most studied and their expression correlates with prognosis and
aggressiveness [63,83]. On the other hand markers of EMT [60] and expression of efflux pumps of
ABCs family are certain markers of CSCs suggesting that the definition of a cluster of biomarkers
could be the best strategy to detect CSCs in EC.
• CSCs related pathways are multiple and crosstalking, suggesting that there is no strict dependency
on a specific pathway. Wnt-βcatenin [76], Notch [89] and Hedgehog [90] are the most important
but also other signaling cascades implied in multiple biological mechanism like ER [113] and
PI3K/AKT pathways [94] are involved in maintaining endometrial CSCs with a main role played
also by epigenetic modulators.
• Nowadays we have few clinical data on drugs targeting CSCs. Certainly, most early phase studies
showed that these drugs are safe but data on activity are lacking. Crosstalk and redundant
pathways maintaining stemness are probably intrinsic mechanisms of resistance in several cancers
and next therapeutic strategies could consider combination of drugs. The addition of drugs
against CSC pathways to chemotherapy could be a tool to overcome resistance in ECs. An even
more promising combination is the one of checkpoint inhibitors with drugs targeting CSCs above
all in inflamed tumors among which MSI-high EC is one of the most interesting example [15,130].
Another powerful strategy could be treatment with chimeric antigen receptor-modified T (CART)
cells, that recognize specific antigens, inducing T cell activation and survival, thus resulting in
antitumor activity [44]. Preclinical works suggest that CSC-targeted CART cells against CD133
are effective in peritoneal carcinomatosis from gynecological cancers PDXs [131] but there is no
ongoing study with CART133 including patients with ECs.
Evaluating toxicities is one of the main challenges for the future, remembering that CSCs could be
targeted also in an indirect way. Among indirect strategies PI3K/AKT inhibitors and hormonal agents
showed interesting activity in EC [120].
7. Conclusions
In conclusion CSCs are crucial in cancer initiation, metastasis and above all, drug resistance
but appear also to be druggable. Nevertheless, diagnostic biomarker validation is essential for the
development of successful, biology oriented therapeutic strategies. Ongoing early phase trials are
evaluating safety of these approaches paving the way for development of a new and fascinating
precision medicine in a setting of poor valuable therapeutic options.
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